Lung cancer remains a leading cause of cancer related mortality worldwide. Despite
numerous advances in treatments over the past decade, non-small cell lung cancer …

Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …

Background Previous phase 2 trials of neoadjuvant anti-PD-1 or anti-PD-L1 monotherapy in
patients with early-stage non-small-cell lung cancer have reported major pathological …

Introduction Programmed death receptor-1 (PD-1) inhibitors have shown efficacy in first-line
treatment of NSCLC; however, evidence of PD-1 inhibitor as neoadjuvant treatment is …

In an ongoing, open-label, single-arm phase II study (NCT02927301), 181 patients with
untreated, resectable, stage IB–IIIB non-small cell lung cancer received two doses of …

Background Individual participant data meta-analyses of postoperative chemotherapy have
shown improved survival for patients with non-small-cell lung cancer (NSCLC). We aimed to …

Surgery remains the only potentially curative modality for early-stage non-small cell lung
cancer (NSCLC) patients and tissue availability is made possible. However, a proportion of …

Improvements in outcomes for patients with resectable lung cancers have plateaued.
Clinical trials of resectable non-small-cell lung cancers with overall survival as the primary …

To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

A high proportion of NSCLC patients present with symptoms in advanced disease stage.
The aim of lung cancer screening is to reduce lung cancer-related mortality by detecting …